WO2012121528A3 - Nanocomposite magnétique spécifique du cancer de la thyroïde et son utilisation - Google Patents

Nanocomposite magnétique spécifique du cancer de la thyroïde et son utilisation Download PDF

Info

Publication number
WO2012121528A3
WO2012121528A3 PCT/KR2012/001617 KR2012001617W WO2012121528A3 WO 2012121528 A3 WO2012121528 A3 WO 2012121528A3 KR 2012001617 W KR2012001617 W KR 2012001617W WO 2012121528 A3 WO2012121528 A3 WO 2012121528A3
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid cancer
magnetic nanocomposite
specific
magnetic
nanocomposite
Prior art date
Application number
PCT/KR2012/001617
Other languages
English (en)
Other versions
WO2012121528A2 (fr
Inventor
Jun Ho Choe
Jung Hee Lee
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Publication of WO2012121528A2 publication Critical patent/WO2012121528A2/fr
Publication of WO2012121528A3 publication Critical patent/WO2012121528A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne un nanocomposite magnétique spécifique du cancer de la thyroïde, et plus particulièrement, un nanocomposite magnétique constitué par des nanoparticules magnétiques qui sont encapsulées dans un polymère biocompatible et par un polypeptide spécifique du cancer de la thyroïde qui est conjugué au polymère biocompatible ; une composition diagnostique pour le dépistage du cancer de la thyroïde comprenant le nanocomposite magnétique selon l'invention ; une méthode pour obtenir des informations sur le diagnostic de cancer de la thyroïde à l'aide du nanocomposite magnétique ; et une méthode thérapeutique associée. Le nanocomposite magnétique selon l'invention est avantageux dans la mesure où il peut être utilisé à la fois pour le diagnostic et le traitement du cancer de la thyroïde.
PCT/KR2012/001617 2011-03-04 2012-03-05 Nanocomposite magnétique spécifique du cancer de la thyroïde et son utilisation WO2012121528A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0019519 2011-03-04
KR20110019519 2011-03-04

Publications (2)

Publication Number Publication Date
WO2012121528A2 WO2012121528A2 (fr) 2012-09-13
WO2012121528A3 true WO2012121528A3 (fr) 2012-11-01

Family

ID=46798640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001617 WO2012121528A2 (fr) 2011-03-04 2012-03-05 Nanocomposite magnétique spécifique du cancer de la thyroïde et son utilisation

Country Status (2)

Country Link
KR (1) KR101468769B1 (fr)
WO (1) WO2012121528A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103449530A (zh) * 2013-09-06 2013-12-18 南京东纳生物科技有限公司 高性能磁性锰锌铁氧体纳米星和纳米团簇的制备方法
CN103665160B (zh) * 2013-12-03 2016-04-13 南昌大学 纯化水溶性纳米氧化铁鼠源性IgG类单抗偶联物的方法
EP3119203A4 (fr) * 2014-03-18 2017-12-27 The Trustees Of The University Of Pennsylvania Système de distribution de polyphosphazène pour des nanocristaux métalliques
WO2016015173A1 (fr) * 2014-07-29 2016-02-04 北京福纳康生物技术有限公司 Procédé de traitement de tumeur permettant de bloquer le système vasculaire tumoral au moyen d'un nanomatériau et source de rayonnement externe
CN106344115A (zh) * 2015-07-17 2017-01-25 成昱 磁力刀及其制备方法和应用
GB2556010A (en) * 2015-08-20 2018-05-16 E Sandstrom Robert Method of attacking target cells
CN105219705B (zh) * 2015-09-06 2019-01-04 广州市第一人民医院 超顺磁性氧化铁纳米粒子在标记干细胞中的应用
CN105195105A (zh) * 2015-09-10 2015-12-30 哈尔滨工业大学宜兴环保研究院 一种磁性纳米吸附剂及其制备方法
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
US10709792B1 (en) 2018-04-06 2020-07-14 Verily Life Sciences Llc Passivated magnetic nanoparticles for cell targeting and methods of preparation and use
CN109172826A (zh) * 2018-10-10 2019-01-11 江苏省肿瘤医院 具有加热、化疗和显像功能的靶向纳米磁粒及其制备方法和用途
CN109091469A (zh) * 2018-10-10 2018-12-28 江苏省肿瘤医院 一种具有加热、化疗和显像功能的新型纳米载药系统制备方法及其使用方法
CN109402052B (zh) * 2018-10-15 2022-02-22 宁波美晶医疗技术有限公司 一种用于捕获血液中外泌体的磁性纳米颗粒的制备方法及其应用
CN110922179B (zh) * 2019-12-06 2021-01-29 深圳信义磁性材料有限公司 一种高磁导率低损耗铁氧体材料及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060163526A1 (en) * 2003-07-10 2006-07-27 Joachim Teller Magnetic nanoparticles having improved magnetic properties
US20060222594A1 (en) * 2005-01-20 2006-10-05 Korea Advanced Institute Of Science And Technology Smart magnetic nanosphere preparation and manufacturing method thereof
US20070112339A9 (en) * 2001-07-25 2007-05-17 Robert Ivkov Magnetic nanoscale particle compositions, and therapeutic methods related thereto
WO2009031859A2 (fr) * 2007-09-06 2009-03-12 Anygen Co., Ltd. Complexe multifonctionnel pour l'imagerie et l'administration de médicaments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112339A9 (en) * 2001-07-25 2007-05-17 Robert Ivkov Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US20060163526A1 (en) * 2003-07-10 2006-07-27 Joachim Teller Magnetic nanoparticles having improved magnetic properties
US20060222594A1 (en) * 2005-01-20 2006-10-05 Korea Advanced Institute Of Science And Technology Smart magnetic nanosphere preparation and manufacturing method thereof
WO2009031859A2 (fr) * 2007-09-06 2009-03-12 Anygen Co., Ltd. Complexe multifonctionnel pour l'imagerie et l'administration de médicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. BARZON ET AL.: "Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse", INTERNATIONAL JOURNAL OF CANCER, vol. 110, 2004, pages 914 - 920 *

Also Published As

Publication number Publication date
WO2012121528A2 (fr) 2012-09-13
KR101468769B1 (ko) 2014-12-08
KR20120100840A (ko) 2012-09-12

Similar Documents

Publication Publication Date Title
WO2012121528A3 (fr) Nanocomposite magnétique spécifique du cancer de la thyroïde et son utilisation
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
HK1178074A1 (en) Compositions and methods for the diagnosis and treatment of tumor
RS20140202A1 (en) BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17
WO2012100206A3 (fr) Marqueurs d'irm, systèmes d'administration et d'extraction, et leurs procédés de fabrication et d'utilisation
EP3046583A4 (fr) Conjugués de pseudo-particules virales destinés au diagnostic et au traitement de tumeurs
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
CA2863681A1 (fr) Utilisation topique d'un agent prebiotique commensal dermique et compositions le contenant
WO2012104275A3 (fr) Systèmes d'administration de nanoparticules, leur préparation et leurs utilisations
MY188911A (en) Methods of treating bladder cancer
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX362089B (es) Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
MX2015001716A (es) Niclosamida para el tratamiento de tumores solidos.
WO2010065329A3 (fr) Nanoparticules pour le traitement du cancer
MX357227B (es) Nanoparticulas basadas en lipidos.
IL222605A0 (en) Apparatus and kit for encapsulating at least one compound for therapeutic and/or diagnostic use in erythrocytes
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EP2548888A4 (fr) Peptide spécifique d'une pathologie parodontale et traitement et diagnostic d'une pathologie parodontale l'incluant
WO2010086838A3 (fr) Vecteurs adénoviraux non ad5 et procédés et utilisations associés
ZA201209452B (en) Gold complexes for use in the treatment of cancer
WO2011085134A8 (fr) Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
IN2012DE00138A (fr)
EP2588866A4 (fr) Diagnostic et traitement de tumeurs cérébrales
WO2011031833A3 (fr) Anticorps anticancéreux pour humains

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12754524

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12754524

Country of ref document: EP

Kind code of ref document: A2